Figure 4: The influence of captopril (cap) treatment (0 and 80 mg/kg) on the total urinary kallikrein levels of diabetic and non-diabetic Wistar Kyoto (WKY) rats. The cap- treatment (40 and 80 mg/kg) produced a significant (p<0.001) increase in total urinary kallikrein compared to the respective diabetic and non-diabetic control (cont) WKY rats. Each column (n=7) represents mean± SEM [57].